These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients. Wang YF; Yang YL; Gao ZF; Zhou CJ; Gregg X; Shi YF; Wang J; Yang XF; Ke XY J Hematol Oncol; 2012 Jul; 5():38. PubMed ID: 22769020 [TBL] [Abstract][Full Text] [Related]
10. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631 [TBL] [Abstract][Full Text] [Related]
11. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. ten Berge RL; de Bruin PC; Oudejans JJ; Ossenkoppele GJ; van der Valk P; Meijer CJ Histopathology; 2003 Nov; 43(5):462-9. PubMed ID: 14636272 [TBL] [Abstract][Full Text] [Related]
12. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. Rassidakis GZ; Sarris AH; Herling M; Ford RJ; Cabanillas F; McDonnell TJ; Medeiros LJ Am J Pathol; 2001 Aug; 159(2):527-35. PubMed ID: 11485911 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Suzuki R; Kagami Y; Takeuchi K; Kami M; Okamoto M; Ichinohasama R; Mori N; Kojima M; Yoshino T; Yamabe H; Shiota M; Mori S; Ogura M; Hamajima N; Seto M; Suchi T; Morishima Y; Nakamura S Blood; 2000 Nov; 96(9):2993-3000. PubMed ID: 11049976 [TBL] [Abstract][Full Text] [Related]
15. Correlation of seven biological factors (Hsp90a, p53, MDM2, Bcl-2, Bax, Cytochrome C, and Cleaved caspase3) with clinical outcomes of ALK+ anaplastic large-cell lymphoma. Li HL; Huang XP; Zhou XH; Ji TH; Wu ZQ; Wang ZQ; Jiang HY; Liu FR; Zhao T Biomed Environ Sci; 2011 Dec; 24(6):630-41. PubMed ID: 22365399 [TBL] [Abstract][Full Text] [Related]
16. Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo. Coluccia AM; Perego S; Cleris L; Gunby RH; Passoni L; Marchesi E; Formelli F; Gambacorti-Passerini C Blood; 2004 Apr; 103(7):2787-94. PubMed ID: 14656879 [TBL] [Abstract][Full Text] [Related]
18. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999 [TBL] [Abstract][Full Text] [Related]
19. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. ten Berge RL; Oudejans JJ; Ossenkoppele GJ; Pulford K; Willemze R; Falini B; Chott A; Meijer CJ J Clin Pathol; 2000 Jun; 53(6):445-50. PubMed ID: 10911802 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein. Ergin M; Denning MF; Izban KF; Amin HM; Martinez RL; Saeed S; Alkan S Exp Hematol; 2001 Sep; 29(9):1082-90. PubMed ID: 11532349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]